文献速递眼底病与葡萄膜炎

辅助局部多佐胺-噻吗洛尔治疗难治性新生血管性年龄相关性黄斑变性的疗效

EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
PubMed 文献 · Retina · 2019-01-01

这项回顾性介入研究纳入15例对抗VEGF治疗无反应的新生血管性AMD患者,在继续固定间隔抗VEGF治疗基础上加用局部多佐胺-噻吗洛尔每日两次。平均随访17.2周后,中央黄斑厚度和最大视网膜下液高度显著下降,但最大色素上皮脱离高度和视力无显著变化,眼压显著降低。

要点

  • 加用局部多佐胺-噻吗洛尔可显著降低难治性新生血管性AMD的中央黄斑厚度和视网膜下液。
  • 最大色素上皮脱离高度和视力在短期随访中无显著改善。
  • 眼压显著下降,提示该辅助治疗可能与降眼压效应相关。

核心结论

  • 辅助局部多佐胺-噻吗洛尔可有效降低难治性新生血管性AMD患者的中央黄斑厚度和视网膜下液,但短期未带来功能改善。

研究设计与样本

  • 回顾性介入研究,纳入15例对抗VEGF治疗无反应的新生血管性AMD患者。
  • 患者每日两次使用局部多佐胺-噻吗洛尔,并继续按原固定间隔和药物接受抗VEGF治疗。

主要发现

  • 平均随访17.2±5.5周,平均中央黄斑厚度从基线383.5 μm降至末次访视298.3 μm(P=0.041)。
  • 平均最大视网膜下液高度从基线105.0 μm降至末次访视58.3 μm(P=0.021)。
  • 11只视网膜下液型眼中3只实现视网膜下液完全吸收。
  • 最大色素上皮脱离高度无显著变化;平均logMAR视力从0.61(20/81 Snellen)降至0.66(20/91 Snellen),无统计学意义(P=0.314)。
  • 平均眼压从基线14.9 mmHg显著降至末次访视12.3 mmHg(P=0.005)。

临床怎么用

  • 对于持续固定间隔抗VEGF治疗仍难治的新生血管性AMD,可考虑加用局部多佐胺-噻吗洛尔作为辅助治疗以减轻黄斑水肿和视网膜下液。
  • 需告知患者该辅助治疗短期可能不会改善视力,主要获益为解剖学改善和眼压下降。

局限性

  • 回顾性研究,样本量小(15例),随访时间短(平均17.2周),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration unresponsive to anti-vascular endothelial growth factor therapy. METHODS: This retrospective, interventional study included 15 patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor. Patients used topical dorzolamide-timolol twice daily in the neovascular age-related macular degeneration eye and received anti-vascular endothelial growth factor therapy at each visit, with the same fixed interval and agent as before the addition of dorzolamide-timolol. Central macular thickness, maximal subretinal fluid height, and maximal pigment epithelial detachment height were measured at baseline and every visit. RESULTS: The mean follow-up period was 17.2 ± 5.5 weeks. The mean central macular thickness decreased from 383.5 μm at baseline to 298.3 μm at the final visit (P = 0.041). The mean maximal subretinal fluid height decreased from 105.0 μm at baseline to 58.3 μm at the final visit (P = 0.021). Complete resolution of subretinal fluid was observed in 3 of 11 subretinal fluid-type eyes. There was no significant change in the maximal pigment epithelial detachment height. The mean logarithm of the minimum angle of resolution visual acuity decreased from 0.61 (20/81 Snellen) at baseline to 0.66 (20/91 Snellen) at final visit, which was not significant (P = 0.314). The mean intraocular pressure decreased significantly from 14.9 mmHg at baseline to 12.3 mmHg at the final visit (P = 0.005). CONCLUSION: The use of adjuvant topical dorzolamide-timolol was effective in decreasing central macular thickness and subretinal fluid in patients with neovascular age-related macular degeneration refractory to continual fixed-interval intravitreal anti-vascular endothelial growth factor therapy, but did not result in functional improvement in this short-term study.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lee JH, Lee SC, Byeon SH, et al. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2019. PMID: 30161096. doi:10.1097/IAE.0000000000002293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。